328 related articles for article (PubMed ID: 33317255)
1. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Jang JW; Kim JS; Kim HS; Tak KY; Nam H; Sung PS; Bae SH; Choi JY; Yoon SK; Roberts LR
Clin Mol Hepatol; 2021 Jan; 27(1):207-218. PubMed ID: 33317255
[TBL] [Abstract][Full Text] [Related]
2. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
Yoo S; Kim JY; Lim YS; Han S; Choi J
J Hepatol; 2022 Oct; 77(4):939-946. PubMed ID: 35643206
[TBL] [Abstract][Full Text] [Related]
3. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
[TBL] [Abstract][Full Text] [Related]
4. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
[TBL] [Abstract][Full Text] [Related]
5. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
[TBL] [Abstract][Full Text] [Related]
6. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
[TBL] [Abstract][Full Text] [Related]
7. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yang H; Bae SH; Nam H; Lee HL; Lee SW; Yoo SH; Song MJ; Kwon JH; Nam SW; Choi JY; Yoon SK; Jang JW
J Hepatol; 2022 Sep; 77(3):632-641. PubMed ID: 35398462
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.
Park YM; Lee SG
World J Gastroenterol; 2016 Nov; 22(44):9836-9843. PubMed ID: 27956808
[TBL] [Abstract][Full Text] [Related]
9. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma.
Saitta C; Tripodi G; Barbera A; Bertuccio A; Smedile A; Ciancio A; Raffa G; Sangiovanni A; Navarra G; Raimondo G; Pollicino T
Liver Int; 2015 Oct; 35(10):2311-7. PubMed ID: 25677098
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma.
Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Batrla-Utermann R; Wang LY; You SL; Hsiao CK; Chen PJ; Chen CJ;
Gut; 2014 Oct; 63(10):1648-57. PubMed ID: 24225939
[TBL] [Abstract][Full Text] [Related]
13. What can we learn from hepatitis B virus clinical cohorts?
Lin CL; Tseng TC; Kao JH
Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
[TBL] [Abstract][Full Text] [Related]
14. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
Gounder PP; Bulkow LR; Snowball M; Negus S; Spradling PR; Simons BC; McMahon BJ
Aliment Pharmacol Ther; 2016 Jun; 43(11):1197-207. PubMed ID: 27061300
[TBL] [Abstract][Full Text] [Related]
15. Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis.
Wong DK; Cheng SCY; Mak LL; To EW; Lo RC; Cheung TT; Seto WK; Fung J; Man K; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2020 Feb; 18(2):449-456. PubMed ID: 31252193
[TBL] [Abstract][Full Text] [Related]
16. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
[TBL] [Abstract][Full Text] [Related]
17. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
[TBL] [Abstract][Full Text] [Related]
18. Impact of AAV2 and Hepatitis B Virus Integration Into Genome on Development of Hepatocellular Carcinoma in Patients with Prior Hepatitis B Virus Infection.
Tatsuno K; Midorikawa Y; Takayama T; Yamamoto S; Nagae G; Moriyama M; Nakagawa H; Koike K; Moriya K; Aburatani H
Clin Cancer Res; 2019 Oct; 25(20):6217-6227. PubMed ID: 31320595
[TBL] [Abstract][Full Text] [Related]
19. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.
Chu CM
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378
[TBL] [Abstract][Full Text] [Related]
20. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan.
Tamori A; Nishiguchi S; Kubo S; Narimatsu T; Habu D; Takeda T; Hirohashi K; Shiomi S
J Med Virol; 2003 Dec; 71(4):492-8. PubMed ID: 14556260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
